Kyverna Therapeutics Inc
NASDAQ:KYTX
Kyverna Therapeutics Inc
Kyverna Therapeutics Inc is a US-based company operating in industry. The company is headquartered in Emeryville, California. The company went IPO on 2024-02-08. Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The firm is focused on developing cell therapies for patients suffering from autoimmune diseases. The firm's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). The company intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. The company is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.
Kyverna Therapeutics Inc is a US-based company operating in industry. The company is headquartered in Emeryville, California. The company went IPO on 2024-02-08. Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The firm is focused on developing cell therapies for patients suffering from autoimmune diseases. The firm's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). The company intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. The company is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.
Pipeline Progress: Chimera has begun its phase one trial for KT61, a first-in-class oral STAT6 degrader, and advanced other key immunology programs.
Strategic Shift: The company is prioritizing immunology, reallocating resources from oncology, with future advancement of oncology assets KT333 and KT253 dependent on partnerships.
IRAK4 Update: Sanofi has expanded KT474 phase two trials by adding more doses and patients, aiming for faster progression to phase three.
Financial Strength: Chimera raised about $600 million in 2024 and ended Q3 with $911 million in cash, providing a runway into mid-2027.
Guidance Maintained: Despite development changes, management expects no change to its cash runway guidance.
Upcoming Catalysts: Key readouts for KT61’s phase one are expected in the first half of 2025, with more updates on immunology programs and trial results anticipated over the next 6–12 months.
